The North America Facial Injectable Market should witness market growth of 8.9% CAGR during the forecast period (2023-2029).
There has been a significant rise in disposable incomes as well as a development in awareness of aesthetic beauty. As more & more people want to enhance their aesthetic appearances, this has changed attitudes toward cosmetic operations. Many people choose face injectables over minimally invasive procedures since they are considered safer and have little to no downtime. These injectables include dermal fillers like hyaluronic acid and calcium hydroxylapatite and neurotoxins like botulinum toxin and hyaluronic acid.
The engagement of prominent companies has expanded due to these encouraging tendencies toward wider use of facial injectables. As a result, these businesses have invested in several R&D projects to create cutting-edge fillers that cater to the unmet demands of their clientele. Along with a rise in procedure volumes, this has resulted in the introduction of several unique products. During the projected period, these favorable aspects are anticipated to significantly impact market growth. Furthermore, the increased use of these items across all demographic groups is a crucial trend anticipated to fuel market expansion.
The ageing population in the US and the desire to maintain one's social and economic mobility are primarily responsible for the country's increased demand for aesthetic operations. Therefore, people between 35 and 50 undergo skin tightening and rejuvenation procedures as preventative steps. Men are also becoming much more popular with aesthetic procedures. To increase their revenue share in the regional market, market players are also focusing on introducing innovative products. As a result, the North American market for facial injectables is anticipated to expand significantly during the forecast period.
The US market dominated the North America Facial Injectable Market by Country in 2022 thereby, achieving a market value of $6,116.7 Million by 2029. The Canada market is showcasing a CAGR of 11.4% during (2023-2029). Additionally, The Mexico market would register a CAGR of 10.4% during (2023-2029).
Based on End-use, the market is segmented into MedSpa, Dermatology Clinics and Hospitals. Based on Product, the market is segmented into Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Poly-L-Lactic Acid (PLLA), Collagen & PMMA Microspheres, Hyaluronic Acid (HA) and Others. Based on Application, the market is segmented into Facial Line Correction, Face Lift, Lip Augmentation, Acne Scar Treatment, Lipoatrophy Treatment and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Suneva Medical, Inc., Medytox Inc., Sinclair Pharma Ltd., Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group), Anika Therapeutics, Inc., Prollenium Medical Technologies Inc., Galderma S.A., and Allergan PLC (AbbVie, Inc.).
There has been a significant rise in disposable incomes as well as a development in awareness of aesthetic beauty. As more & more people want to enhance their aesthetic appearances, this has changed attitudes toward cosmetic operations. Many people choose face injectables over minimally invasive procedures since they are considered safer and have little to no downtime. These injectables include dermal fillers like hyaluronic acid and calcium hydroxylapatite and neurotoxins like botulinum toxin and hyaluronic acid.
The engagement of prominent companies has expanded due to these encouraging tendencies toward wider use of facial injectables. As a result, these businesses have invested in several R&D projects to create cutting-edge fillers that cater to the unmet demands of their clientele. Along with a rise in procedure volumes, this has resulted in the introduction of several unique products. During the projected period, these favorable aspects are anticipated to significantly impact market growth. Furthermore, the increased use of these items across all demographic groups is a crucial trend anticipated to fuel market expansion.
The ageing population in the US and the desire to maintain one's social and economic mobility are primarily responsible for the country's increased demand for aesthetic operations. Therefore, people between 35 and 50 undergo skin tightening and rejuvenation procedures as preventative steps. Men are also becoming much more popular with aesthetic procedures. To increase their revenue share in the regional market, market players are also focusing on introducing innovative products. As a result, the North American market for facial injectables is anticipated to expand significantly during the forecast period.
The US market dominated the North America Facial Injectable Market by Country in 2022 thereby, achieving a market value of $6,116.7 Million by 2029. The Canada market is showcasing a CAGR of 11.4% during (2023-2029). Additionally, The Mexico market would register a CAGR of 10.4% during (2023-2029).
Based on End-use, the market is segmented into MedSpa, Dermatology Clinics and Hospitals. Based on Product, the market is segmented into Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Poly-L-Lactic Acid (PLLA), Collagen & PMMA Microspheres, Hyaluronic Acid (HA) and Others. Based on Application, the market is segmented into Facial Line Correction, Face Lift, Lip Augmentation, Acne Scar Treatment, Lipoatrophy Treatment and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Suneva Medical, Inc., Medytox Inc., Sinclair Pharma Ltd., Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group), Anika Therapeutics, Inc., Prollenium Medical Technologies Inc., Galderma S.A., and Allergan PLC (AbbVie, Inc.).
Scope of the Study
By End-use
- MedSpa
- Dermatology Clinics
- Hospitals
By Product
- Botulinum Toxin Type A
- Calcium Hydroxylapatite (CaHA)
- Poly-L-Lactic Acid (PLLA)
- Collagen & PMMA Microspheres
- Hyaluronic Acid (HA)
- Others
By Application
- Facial Line Correction
- Face Lift
- Lip Augmentation
- Acne Scar Treatment
- Lipoatrophy Treatment
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Ipsen Pharma Biotech SAS
- Merz Pharma GmbH & Co. KGaA
- Suneva Medical, Inc.
- Medytox Inc.
- Sinclair Pharma Ltd.
- Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group)
- Anika Therapeutics, Inc.
- Prollenium Medical Technologies Inc.
- Galderma S.A.
- Allergan PLC (AbbVie, Inc.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Facial Injectable Market by End-use
Chapter 4. North America Facial Injectable Market by Product
Chapter 5. North America Facial Injectable Market by Application
Chapter 6. North America Facial Injectable Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Ipsen Pharma Biotech SAS
- Merz Pharma GmbH & Co. KGaA
- Suneva Medical, Inc.
- Medytox Inc.
- Sinclair Pharma Ltd.
- Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group)
- Anika Therapeutics, Inc.
- Prollenium Medical Technologies Inc.
- Galderma S.A.
- Allergan PLC (AbbVie, Inc.)
Methodology
LOADING...
